Last reviewed · How we verify
INTERFERON ALFACON-1
Interferon Alfacon-1 is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | INTERFERON ALFACON-1 |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
Common side effects
Key clinical trials
- Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (PHASE3)
- Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C (PHASE3)
- Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C
- Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial (PHASE3)
- A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C (PHASE2)
- Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C (PHASE3)
- Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin (PHASE4)
- Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |